The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback